Clinical application of CNS-Acting agents in FSD

Journal of Sexual Medicine

Volumn 4, Issue SUPPL. 4, 2007, Pages 280-290

  Perelman, Michael A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

CNS; CombinationTherapy; Female Sexual Dysfunction; Multidisciplinary Approach; Sexual Tipping Point

Indexed keywords

AMFEBUTAMONE; ANDROGEN; BREMELANOTIDE; CENTRAL NERVOUS SYSTEM AGENTS; CONJUGATED ESTROGEN; ESTROGEN; FLIBANSERIN; GINKGO BILOBA EXTRACT; GRANISETRON; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; FLUSHING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEADACHE; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE RESPONSE; HUMAN; MENOPAUSAL SYNDROME; MONOTHERAPY; NAUSEA AND VOMITING; NOSE CONGESTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL COUNSELING; SEXUAL SATISFACTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 35648981057     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00611.x     Document Type: Article

References (68)

1. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, Graziottin A, Heiman J, Laan E, Leiblum S, Padma-Nathan H, Rosen R, Segraves K, Segraves RT, Shabsigh R, Sipski M, Wagner G, Whipple B. Report of the international consensus development conference on female sexual dysfunction: Definitions and classifications. J Urol 2000; 163: 888-93.
2. Halaris A. Neurochemical aspects of the sexual response cycle. CNS Spectr 2003; 8: 211-6.
3. Imbimbo C, Gentile V, Palmieri A, Longo N, Fusco F, Granata AM, Verze P, Mirone V. Female sexual dysfunction: An update on physiopathology. J Endocrinol Invest 2003; 26(3 suppl): 102-4.
4. Munarriz R, Kim NN, Goldstein I, Traish AM. Biology of female sexual function. Urol Clin North Am 2002; 29: 685-93.
5. Scepkowski LA, Georgescu M, Pfaus JG. Neuroendocrine factors in sexual desire and motivation. In: Goldstein I, Traish A, Davis S, Meston C, eds. Women's sexual function and dysfunction. London: Taylor & Francis Ltd; 2005.
6. Fourcroy JL. Female sexual dysfunction: Potential for pharmacotherapy. Drugs 2003; 63: 1445-57.
7. Nijland E, Davis S, Laan E, Schultz WW. Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction. J Sex Med 2006; 3: 763-77.
8. Masters WH, Johnson VE. Human sexual inadequacy. Boston: Little Brown; 1970.
9. Kaplan HS. The new sex therapy. New York: Brunner/Mazel; 1974.
10. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. In: Rosen R, Davis C, Ruppel H, eds. Annual review of sex research. Mount Vernon, IA: The Society for the Scientific Study of Sexuality; 1998.
11. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404.
12. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. J Urol 2003; 170: 2333-8.
13. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11: 367-77.
14. Gambrell RD Jr, Bernard DM, Sanders BI, Vanderburg N, Buxton SJ. Changes in sexual drives of patients on oral contraceptives. J Reprod Med 1976; 17: 165-71.
15. Leeton J, McMaster R, Worsley A. The effects on sexual response and mood after sterilization of women taking long-term oral contraception: Results of a double-blind cross-over study. Aust N Z J Obstet Gynaecol 1978; 18: 194-7.
16. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A. Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-5.
17. Lue T. Erectile dysfunction. N Engl J Med 2000; 342: 1802-13.
18. Park K, Moreland RB, Goldstein I, Atala A, Traish A. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998; 249: 612-7.
19. US Food and Drug Administration. Registry of clinical trials. 2007. Available at: http://www.clinicalstudyresults.org/search/ (accessed July 2, 2007).
20. Segraves R, Balon R, Clayton A. Proposal for changes in diagnostic criteria for sexual dysfunctions. J Sex Med 2007; 4: 567-80.
21. Kielbasa LA, Daniel KL. Topical alprostadil treatment of female sexual arousal disorder. Ann Pharmacother 2006; 40: 1369-76.
22. Burger HG, Papalia MA. A clinical update on female androgen insufficiency - Testosterone testing and treatment in women presenting with low sexual desire. Sex Health 2006; 3: 73-8.
23. Bachmann G, Oza D. Female androgen insufficiency. Obstet Gynecol Clin North Am 2006; 33: 589-98.
24. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-8.
25. Simon J. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Endocrin Metab 2005; 90: 5226-33.
26. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005; 165: 1582-9.
27. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab 2006; 91: 3697-716.
28. Traish A, Guay A, Spark RF. Are the Endocrine Society's Clinical Practice Guidelines on androgen therapy in women misguided? A commentary. J Sex Med 2007; 4: 1223-35.
29. Schwenkhagen A. Hormonal changes in menopause and implications on sexual health. J Sex Med 2007; 4(3 suppl): 220-6.
30. Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med 2007; 4(3 suppl): 235-53.
31. Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: Systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003; 188: 286-93.
32. Meston CM, McCall KM. Dopamine and norepinephrine responses to film-induced sexual arousal in sexually functional and sexually dysfunctional women. J Sex Marital Ther 2005; 31: 303-17.
33. Park K, Kang HK, Seo JJ, Kim HJ, Ryu SB, Jeong GW. Blood-oxygenation-level-dependent functional magnetic resonance imaging for evaluating cerebral regions of female sexual arousal response. Urology 2001; 57: 1189-94.
34. Karama S, Lecours AR, Leroux JM, Bourgouin P, Beaudoin G, Joubert S, Beauregard M. Areas of brain activation in males and females during viewing of erotic film excerpts. Hum Brain Mapp 2002; 16: 1-13.
35. Gizewski ER, Krause E, Karama S, Baars A, Senf W, Forsting M. There are differences in cerebral activation between females in distinct menstrual phases during viewing of erotic stimuli: A fMRI study. Exp Brain Res 2006; 174: 101-8.
36. Komisaruk BR, Whipple B. Functional MRI of the brain during orgasm in women. Ann Rev Sex Res 2005; 16: 62-86.
37. Park K, Jeong GW. The role of functional MRI in neural assessment of female sexual dysfunction. Curr Sex Health Rep 2007; 4: 33-40.
38. Smith PJ, Talbert RL. Sexual dysfunction with antihypertensive and antipsychotic agents. Clin Pharm 1986; 5: 373-84.
39. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: A critical review. J Clin Psychopharmacol 1999; 19: 67-85.
40. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, Seibyl JP, Innis RB. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003; 28: 413-20.
41. Perelman MA. A new combination treatment for premature ejaculation: A sex therapist's perspective. J Sex Med 2006; 3: 1004-12.
42. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002; 168: 2359-67.
43. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, Beyenburg S. "Dopamine-dependent"side effects of selective serotonin reuptake inhibitors: A clinical review. J Clin Psychiatry 2004; 65: 1064-8.
44. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006; 59: 203-10.
45. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006; 9: 27-32.
46. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: A randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001; 158: 805-7.
47. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006; 67: 736-46.
48. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005; 66: 844-8. 8
49. Taylor MJ. Strategies for managing antidepressant-induced sexual dysfunction: A review. Curr Psychiatry Rep 2006; 8: 431-6.
50. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev 2002; 8: 117-42.
51. ClinicalTrials.gov. Clinical Trials registry Web site. 2007. Available at: http://clinicaltrials.gov/ct/search?term=flibanserin&submit= Search (accessed July 20, 2007).
52. Voisey J, Carroll L, van Daal A. Melanocortins and their receptors and antagonists. Curr Drug Targets 2003; 4: 586-97.
53. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003; 994: 96-102.
54. Diamond LE, Earle DC, Heiman JC, Rosen RC, Perelman MA, Harning R. An Effect on the subjective sexual response in premenopausal women with Sexual Arousal Disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3: 628-38.
55. Rellini A, Meston C. The sensitivity of event logs, self-administered questionnaires and photoplethysmography to detect treatment-induced changes in Female Sexual Arousal Disorder (FSAD) diagnosis. J Sex Med 2006; 3: 283-91.
56. Perelman MA, Levine SB, Fendl J, Fischkoff S. Randomized, placebo-controlled, crossover study to evaluate the effects of intranasal bremelanotide on perceptions of desire and arousal in postmenopausal women with Sexual Arousal Disorder. Presented during the annual meeting of the International Society for the Study of Women's Sexual Health (ISSWHS) February 25, 2007, Orlando, FL.
57. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. In: Rosen R, Davis C, Ruppel H, eds. Annual review of sex research. Mount Vernon, IA: The Society for the Scientific Study of Sexuality; 1998.
58. Perelman M. The Sexual Tipping Point TM: A model to conceptualize etiology, diagnosis & combination treatment of female and male sexual dysfunction. J Sex Med 2006; 3(1 suppl): 52. [abstract 121)]
59. Perelman MA. Psychosocial evaluation and combination treatment of men with erectile dysfunction. Urol Clin North Am 2005; 32: 431-45.
60. Perelman MA. Integrated sex therapy: Interplay of behavioral, cognitive, and medical approaches. In: Carson CC, Goldstein I, Kirby RS, eds. Textbook of erectile dysfunction. 2nd edition. London: Informa Healthcare; 2008 (in press).
61. Sadovsky R. Optimizing response to phosphodiesterase type 5 inhibitors. Curr Sex Health Rep 2007; 4: 1-6.
62. Pauls RN, Kleeman SD, Karram MM. Female sexual dysfunction: Principles of diagnosis and therapy. Obstet Gynecol Surv 2005; 60: 196-205.
63. Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, eds. Sexual medicine: Sexual dysfunc tions in men and women. Paris: Health Publications; 2004.
64. Althof SE, Leiblum SR, Chevert-Measson M, Hartmann U, Levine SB, McCabe M, Plaut M, Rodrigues O, Wylie K. Psychological and interpersonal dimensions of sexual function and dysfunction. In: Lue TF, Basson R, Rosen RC, et al., eds. Sexual medicine: Sexual dysfunctions in men and women. Paris: Health Publications; 2004.
65. Perelman MA. Combination therapy for sexual dysfunction: Integrating sex therapy and pharmacotherapy. In: Balon R, Segraves RT, eds. Handbook of sexual dysfunction. Boca Raton: Taylor & Francis; 2005.
66. Hurlbert DF, Apt C, Hurlbert MK, Pierce AP. Sexual compatibility and the sexual desire-motivation relation in females with hypoactive sexual desire disorder. Behav Modif 2000; 24: 325-47.
67. Bancroft J. Central inhibition of sexual response in the male: A theoretical perspective. Neurosci Biobehav Rev 1999; 23: 763-84.
68. Goldstein I, Meston CM, Davis SR, Traish AM, eds. Women's sexual function and dysfunction. 1st edition. London: Taylor & Francis; 2006.